What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?
What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?
Pfizer highlighted several factors affecting its 2024 EPS that won't carry over to 2025.Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance.
輝瑞公司（紐交所：PFE）將在週二召開投資者電話會議，提供2025財年的全面財務指導。
Ahead of the call, Goldman Sachs has outlined its expectations for the guide and commentary on the upcoming year.
在電話會議之前，高盛已概述了其對指導意見和即將到來的年度的預期。
The analyst anticipates that Pfizer's management will guide to EPS in the mid-to-high $2 range with core business growth offset by the $0.30 in favorable but non-recurring items during 2024.
分析師預計輝瑞管理層將指導每股收益在2美元中高區間，而核心業務增長將被2024年0.30美元的有利但非經常性項目所抵消。
Pfizer highlighted several factors affecting its 2024 EPS that won't carry over to 2025.
輝瑞強調了幾個影響其2024年每股收益的因素，這些因素不會延續到2025年。
The 2024 EPS includes one-time boosts: a $1.2 billion benefit from Paxlovid stockpiling and a U.S. government true-up and equity income from its stake in Haleon Plc (NYSE:HLN). However, Haleon income will not appear in 2025, as Pfizer's ownership in Haleon is dropping below 20%.
2024年的每股收益包括一次性提升：來自Paxlovid庫存積累的12億美金收益以及美國政府的補償和其在Haleon Plc（紐交所：HLN）股份的權益收入。然而，Haleon的收入在2025年將不會出現，因爲輝瑞在Haleon的持股比例已降至20%以下。
Goldman forecasts for 2025 revenues of $64.9 billion and EPS of $3.13, which compares to consensus estimates of $63.2 billion and $2.89, respectively.
高盛預測2025年收入爲649億美金，每股收益爲3.13美元，而共識預期爲632億美金和2.89美元。
Goldman Sachs notes that the impact of the IRA Part D redesign will likely be addressed in the company's 2025 guidance. However, the analyst does not expect the details to be broken down by individual products but instead based on the overall commercial portfolio.
高盛指出，IRA Part D重組的影響可能將在公司2025年的指導中得到解決。然而，分析師不希望細節按單個產品進行區分，而是基於整體商業組合。
The analyst expects Paxlovid sales of $4.3 billion vs. consensus of $3.7 billion, though slightly more conservative on Vyndaqel sales of $5.9 billion vs. consensus of $6.2 billion.
分析師預計Paxlovid的銷售額爲43億美金，而共識爲37億美金，儘管對Vyndaqel的銷售額略爲保守，預計爲59億美金，而共識爲62億美金。
Year-to-date, Eliquis has performed well, showing 12% growth thanks to market expansion and increased market share. This growth has been supported by Pfizer's commercial team and boosted by Part D catastrophic coverage in 2024.
截至目前，阿哌沙班表現良好，因市場擴張和市場份額增加而增長12%。這一增長得益於輝瑞的商業團隊，並受到2024年D類藥物災難性覆蓋的推動。
Looking ahead to 2025, Pfizer expects continued growth opportunities driven by market expansion and the potential for further share gains.
展望2025年，輝瑞預計將持續獲得由市場擴張和進一步市場份額增長潛力驅動的增長機會。
"We highlight dynamics across key topics and frame potential points of discussion with potential read-across beyond Pfizer specifically, noting that they are the only large cap pharma company in our coverage that we expect to opine on 2025 ahead of the new year," Goldman analyst writes.
「我們強調關鍵話題的動態，並框定潛在討論的切入點，指出輝瑞特定之外的潛在延伸，並注意到它是我們覆蓋的唯一一家我們預計將在新年前對2025年發表意見的大盤製藥公司，」高盛的分析師寫道。
Price Action: PFE stock is down 0.39% at $25.48 at last check Monday.
價格動態：截至週一最後檢查，輝瑞股票下跌0.39%，報25.48美元。
- Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
- Ozempic製造商諾和諾德投資超過10億在新的丹麥生產設施，計劃從Catalent再增加3個。
Photo via Shutterstock.
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。
